Vídeos

Ômega 3 nos últimos estudos



Palestrantes:
Dra. Adriana Bertolami
Médica da Seção de Dislipidemias e do Laboratório do Sono do Instituto Dante Pazzanese
Diretora Administrativa do Departamento de Aterosclerose - Biênio 2018/2019
e
Dra. Maria Cristina de Oliveira Izar
Professora Livre-Docente da Disciplina de Cardiologia da Universidade Federal de São Paulo
Presidente do Departamento de Aterosclerose - Biênio 2018/2019

Referências:
1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447-55.
2. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8.
3. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015-26.
4. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al.; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152-9.
5. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.
6. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540-50.
7. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812792

Desenvolvido pela Diretoria de Tecnologia da SBC
Todos os Direitos Reservados © Copyright 2015
Sociedade Brasileira de Cardiologia | Tecnologia@cardiol.br